Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899481 | 1.00 | NPC1 (0.66) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL6418495 | 0.92 | NR4A2 (0.72) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL2493105 | 0.89 | NPC1 (0.64) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL6418497 | 0.89 | NR4A2 (0.68) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL30697204 | 0.89 | NPC1 (0.64) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL4164843 | 0.88 | NPC1 (0.63) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL6332786 | 0.87 | NPC1 (0.61) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL23551106 | 0.85 | NPC1 (0.60) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL3243814 | 0.85 | MAPT (0.67) | NPC1NR4A2CREBBPKIF11ASH1L | |
| SCHEMBL7415993 | 0.85 | NPC1 (0.64) | NPC1NR4A2CREBBPKIF11ASH1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118108706-A | Glutarimide | C4医药公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-111278815-B | Glutarimide | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| EP-3679026-A1 | GLUTARIMIDE | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2019043214-A1 | GLUTARIMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| EP-1979315-A2 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802131-B2 | Glutarimides for medical treatment | CRBN, GCDH, GCLC | NPC1 3330/4885NR4A2 1121/4885CREBBP 263/4885 |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | NPC1 3330/4885NR4A2 1121/4885CREBBP 263/4885 |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | NPC1 3330/4885NR4A2 1121/4885CREBBP 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.